Brii Biosciences has recently made an announcement regarding its strategic agreements with Qpex Biopharma and other third parties. Under the terms of the agreement, Brii Bio has reached an agreement to acquire exclusive global rights for the development and commercialisation of BRII-693 (also known as QPX9003). Previously, Brii Bio held exclusive rights to this product in Greater China, but with this agreement, it will expand its rights globally. As part of the agreement, Brii Bio will return its exclusive rights to QPX7728-based products, namely BRII-636 and BRII-672, in Greater China to Qpex. This means that Brii Bio will no longer have exclusive rights to develop and commercialise these products in Greater China. BRII-693 is a novel synthetic lipopeptide being developed specifically for the treatment of critically ill patients who are suffering from multidrug-resistant (MDR) or extensively drug-resistant (XDR) gram-negative bacterial infections. These infections, particularly caused by carbapenem-resistant strains of Acinetobacter baumannii and Pseudomonas aeruginosa, pose a significant challenge in healthcare settings due to their resistance to commonly used antibiotics.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!